Related Experiment Video
Updated: Mar 28, 2026

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
High-Sensitivity Troponin I and Rhythm Outcome after Electrical Cardioversion for Persistent Atrial Fibrillation
Anja Wiedswang Horjen1, Sara Reinvik Ulimoen, Ingebjørg Seljeflot
1Department of Medical Research, Vestre Viken Hospital Trust, Bx00E6;rum Hospital, Drammen, Norway.
Insights
High-sensitivity troponin I (hs-TnI) did not predict atrial fibrillation (AF) recurrence after cardioversion. hs-TnI levels remained stable in patients maintaining sinus rhythm and were unaffected by candesartan treatment.
Area of Science:
- Cardiology
- Biomarkers
- Electrophysiology
Background:
- Persistent atrial fibrillation (AF) poses a significant clinical challenge.
- Cardioversion is a common procedure to restore sinus rhythm.
- Predictors of long-term rhythm outcome after cardioversion are crucial for patient management.
Purpose of the Study:
- To investigate if high-sensitivity troponin I (hs-TnI) predicts long-term rhythm outcome after cardioversion for persistent AF.
- To determine if maintaining sinus rhythm or candesartan treatment reduces hs-TnI levels.
Main Methods:
- A double-blind, placebo-controlled study involving 171 patients undergoing electrical cardioversion for AF.
- Patients were randomized to receive candesartan or placebo.
- hs-TnI levels were measured at baseline and study end in successfully cardioverted patients.
Main Results:
- hs-TnI was detectable in all subjects, with a median baseline of 5.3 ng/l.
- Baseline hs-TnI did not predict rhythm outcome 6 months post-cardioversion.
- Candesartan treatment did not affect hs-TnI levels, nor did maintaining sinus rhythm.
Conclusions:
- hs-TnI is not a predictor of AF recurrence after cardioversion.
- Maintaining sinus rhythm for 6 months does not alter hs-TnI levels.
- Candesartan does not influence hs-TnI levels in this context.
Objectives:
We hypothesised that high-sensitivity troponin I (hs-TnI) might predict long-term rhythm outcome after cardioversion for persistent atrial fibrillation (AF), and that maintenance of sinus rhythm and/or treatment with the angiotensin II type 1 receptor blocker candesartan would reduce hs-TnI levels.
Methods:
In a double-blind, placebo-controlled study, 171 patients referred for electrical cardioversion for AF were randomised to receive candesartan or placebo for 3-6 weeks before cardioversion and for 6 months after electrical cardioversion. Blood samples for analysis of hs-TnI (Abbott Diagnostics) were available in 129 patients at baseline and in 60 successfully cardioverted patients at study end.
Results:
Hs-TnI was detectable in all subjects, with a median value of 5.3 ng/l (25th percentile 3.7, 75th percentile 7.2). hs-TnI at baseline was not predictive of rhythm outcome 6 months after electrical cardioversion for persistent AF. Treatment with candesartan did not influence the levels of hs-TnI. hs-TnI was unchanged from baseline to study end in patients who maintained sinus rhythm [4.9 (3.7, 7.0) and 5.0 (4.0, 6.4) ng/l, respectively; p = 0.699).
Conclusions:
hs-TnI did not predict AF recurrence after cardioversion. hs-TnI levels were unchanged in patients maintaining sinus rhythm for 6 months after electrical cardioversion. hs-TnI levels were not influenced by treatment with candesartan.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Electrophysiology of Normal Cardiac Rhythm
Pulse rhythm
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...

